Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | IL2 | P60568 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL610146 | 0.90 | LMNA (0.43) | HTTLMNAMAPTKDM4EATM | |
| SCHEMBL18987373 | 0.89 | LMNA (0.42) | HTTLMNAMAPTKDM4EATM | |
| SCHEMBL28139638 | 0.85 | HTT (0.40) | HTTLMNAMAPTKDM4EATM | |
| SCHEMBL5778345 | 0.83 | LMNA (0.43) | HTTLMNAMAPTKDM4EATM | |
| SCHEMBL2886677 | 0.82 | KDM4E (0.59) | HTTLMNAMAPTKDM4EATM | |
| SCHEMBL9088744 | 0.80 | HTT (0.43) | HTTLMNAMAPTKDM4EATM | |
| SCHEMBL9330422 | 0.78 | ATM (0.48) | HTTLMNAMAPTKDM4EATM | |
| SCHEMBL8630585 | 0.77 | KDM4E (0.47) | HTTLMNAMAPTKDM4EATM | |
| SCHEMBL8622918 | 0.75 | HTT (0.47) | HTTLMNAMAPTKDM4EATM | |
| SCHEMBL9330931 | 0.75 | ATM (0.51) | HTTLMNAMAPTKDM4EATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2925323-B1 | AN INHIBITOR OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2017-05-17 | — | — | EP | disclosed |
| EP-2925323-B1 | AN INHIBITOR OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2017-05-17 | — | — | EP | disclosed |
| US-20150290192-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150290192-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150290192-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. | 2015-10-15 | — | — | US | disclosed |
| EP-2925323-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. Hoffmann-La Roche AG (CH) | 2015-10-07 | — | — | EP | disclosed |
| CN-104968346-A | Inhibitors of bruton's tyrosine kinase | HOFFMANN LA ROCHE | 2015-10-07 | — | — | CN | disclosed |
| CN-103153984-B | Inhibitors of bruton's tyrosine kinase | HOFFMANN LA ROCHE | 2015-04-22 | — | — | CN | disclosed |
| US-8940741-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940741-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-20130178461-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-8481540-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481540-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481540-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2013-07-09 | — | — | US | disclosed |
| EP-2603500-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F.HOFFMANN-LA ROCHE AG (CH) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012020008-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012020008-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-16 | — | — | WO | disclosed |
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN JOSEPH (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN JOSEPH (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BERTHEL STEVEN JOSEPH (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150290192-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, ABL1 | HTT 3503/4885LMNA 2550/4885MAPT 3633/4885 |
| US-20120040949-A1 | Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LYN | HTT 4501/4885LMNA 4654/4885MAPT 4109/4885 |
| US-20130178461-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | HTT 4501/4885LMNA 4654/4885MAPT 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.